Expedition Therapeutics Enters a ~$645M Licensing Deal with Fosun Pharma for XH-S004

Shots: Fosun Pharma has granted Expedition global rights to develop, manufacture, & commercialize XH-S004, excl. Mainland China, Hong Kong SAR, & Macau SAR, where Fosun will retain its rights As per the deal, Fosun will receive $120M incl. upfront & development milestone payments, with ~$525M in sales milestones XH-S004 (DPP-1 inhibitor, PO) is being investigated…

ByRidhi RastogiAugust 12, 2025

Teva Partners with Fosun Pharma to Accelerate Development of TEV-56278 in Immuno-Oncology

Shots: Teva & Fosun Pharma have partnered to advance the development of TEV-56278 in immuno-oncology & accelerate global clinical data generation As per the deal, Fosun will receive an exclusive license to develop, manufacture & commercialize TEV-56278 in mainland China, Hong Kong SAR, Macau SAR & Taiwan as well as select Southeast Asian countries, while…

ByRidhi RastogiJune 17, 2025

Top COVID-19 Deals (Part II): Biopharma Vaccine Development

The recent emergence of the coronavirus SARS-CoV-2 and the COVID-19 pandemic has spurred global healthcare and life sciences companies- as well as government agencies- to partner at unprecedented speed to develop vaccines- treatments- and tests This article covers the last four months of deal data provided by Chris Dokomajilar of DealForma Our team at PharmaShots…

ByPrince GiriMay 1, 2020

Expedition Therapeutics Enters a ~$645M Licensing Deal with Fosun Pharma for XH-S004

Teva Partners with Fosun Pharma to Accelerate Development of TEV-56278 in Immuno-Oncology

Top COVID-19 Deals (Part II): Biopharma Vaccine Development

Contact US

OUR INFORMATION

FOLLOW US